1H Revenues: €77.4 million (+20%)
1H Loss: €5.4 million (loss of €11.3 million 1H12)
Comments: R&D division revenues were €49.1 million, up 56% driven by revenue recognition on the upfront payment from AbbVie in the global collaboration on GLPG0634. Services revenues were down 14% to €28.4 million. Results include the closure and relocation of the Basel site activities in 1H12, and the Cangenix acquisition this year.